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INTRODUCTION
Complications of the lung after bone marrow transplan-
tation (BMT) contribute significantly to morbidity and
mortality. Idiopathic pneumonia syndrome (IPS) of nonin-
fectious etiology usually leads to progressive respiratory fail-
ure and accounts for the majority of lung-related deaths early
posttransplantation [1]. The risk of developing IPS is related
to the severity of conditioning and the degree of allogenicity
of the BM graft [2]. We have developed a murine model of
IPS in which the generation of lung injury is dependent on
the coinfusion of allogeneic T cells with the BM inoculum
and is potentiated by intense pre-BMT conditioning such as
that achieved with cyclophosphamide (Cy) and lethal irradia-
tion [3]. In our mouse model, the initial inﬂux into the lung
comprises host monocytes as early as day 3 post-BMT. Sub-
sequently, both CD4+ and CD8+ donor T cells migrate into
the lung, where they encounter the activated host mono-
cytes. By day 7 post-BMT, lung dysfunction presents as
reduced speciﬁc compliance, decreased total lung capacity,
and increased wet and dry lung weights. Histologically, IPS
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ABSTRACT
Following allogeneic bone marrow transplantation (alloBMT), idiopathic pneumonia syndrome (IPS) and graft-versus-
host disease (GVHD) caused by donor cell alloreactivity remain major obstacles to a successful outcome. Intercellu-
lar adhesion molecule-1 (ICAM-1) is an adhesion molecule that is involved in regulating lymphohematopoietic cell
migration and facilitating T-cell responses. To determine whether ICAM-1 expression in the host would affect IPS
or GVHD tissue injury responses, ICAM-1–/– mice were compared with ICAM-1+/+ controls. ICAM-1–/– recipients
did not exhibit the manifestations of IPS injury such as an increase in lung weights nor decreased lung function.
The influx of T cells, macrophages, and neutrophils was dramatically dampened as was the production of the inflam-
matory cytokines interferon-γ and tumor necrosis factor α and the chemokines monocyte chemotactic protein 1,
macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and lymphotactin, normally upregulated in the lung dur-
ing IPS. In contrast, systemic levels of these mediators were unaffected and GVHD-induced lesions in the liver and
colon did not differ in severity regardless of ICAM-1 expression. GVHD-mediated mortality was accelerated in
ICAM-1–/– recipients at doses of allogeneic spleen cells that are otherwise not uniformally lethal. These data impli-
cate ICAM-1 as playing a critical role in the generation of IPS; therefore, ICAM-1 may be a discerning element,
segregating IPS from GVHD injury post-alloBMT.
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is associated with injured alveolar type II cells and increased
frequencies of cells expressing B7.1/B7.2 (costimulatory for
T cells) and the cytolytic protein granzyme B (expressed by
CD8+ T cells) [4]. Bronchoalveolar lavage (BAL) fluid of
mice with IPS contain elevated levels of the inflammatory
cytokines tumor necrosis factor (TNF)-α and interferon
(IFN)-γ as well as increased levels of nitrite, lactate dehydro-
genase, and protein, all indices of lung injury [4,5]. IPS
development is certainly associated with the presence of
graft-versus-host disease (GVHD)-causing T cells, but
because some degree of allogenicity may be beneﬁcial in pre-
venting leukemic relapse and promoting BM engraftment in
humans, measures to hinder the adhesion, extravasation, and
recruitment of inflammatory cells in the early post-BMT
period may provide alternative strategies.
Recently, we reported that monocyte- and T-cell–
attracting chemokines are produced in the lung during the
generation of murine IPS [6]. Chemokines regulate leuko-
cyte functioning and migration [7]. They activate and facili-
tate leukocyte–endothelial cell interactions such as rolling,
adhesion, and transmigration by the induction of high-afﬁnity
states and lateral mobility of surface adhesion molecules and
integrins that stabilize the interaction [8,9]. Intercellular
adhesion molecule-1 (ICAM-1, CD54) is expressed on endo-
thelial cells and epithelial cells, including alveolar epithelium,
and is one of the ligands for leukocyte function–associated
antigen 1 (LFA-1, CD11a) and Mac-1 (CD11b), the β2 inte-
grins expressed by leukocytes [10,11]. ICAM-1 can also be
expressed by monocytes, dendritic cells, and lymphocytes.
Mice deﬁcient in ICAM-1 (ICAM-1–/–) are impaired in neu-
trophil migration in vivo and in the induction of allogeneic
responses in vitro [12]. ICAM-1 is also an important costim-
ulatory molecule for T cells [13,14], and the ICAM-1:LFA-1
interaction is important in the induction of sensitization to
major histocompatability complex (MHC) alloantigens and
allograft rejection [15,16]. We and others have previously
demonstrated that ICAM-1 is upregulated in GVHD target
organs (spleen, liver, colon) early following allogeneic BMT
(alloBMT) in mice and humans [17-20] and that blockade of
the LFA-1:ICAM-1/ICAM-2 interaction with anti–LFA-1
and/or anti–ICAM-1 antibodies can ameliorate T-cell–
mediated GVHD in rodents [17,21-23].
Through the use of neutralizing antibodies to ICAM-1
and LFA-1 or using ICAM-1 knockout mice, the impor-
tance of ICAM-1 upregulation in response to inﬂammatory-
mediator release has been demonstrated in various rodent
models of lung inﬂammation and injury such as that induced
by bleomycin, irradiation, endotoxin, respiratory viral ill-
ness, and pancreatitis [24-31]. This interaction also influ-
ences the adherence of alloreactive T-helper type 1 (Th1)
cells in the lung following adoptive transfer [32].
In this study, we wanted to determine whether interfer-
ence with leukocyte attachment and/or migration will inﬂu-
ence the generation of IPS following alloBMT. The goal of
this investigation was to examine the role of recipient
ICAM-1 expression in BMT-induced lung injury. We found
that ICAM-1 is normally upregulated in the lung during IPS
and, by using ICAM-1–/– recipient mice, that its deﬁciency
ameliorates IPS manifestations. In contrast, we showed that
host ICAM-1 deficiency does not affect GVHD-induced
lesions in liver and colon and that ICAM-1–/– mice exhibit
increased GVHD-mediated mortality. Therefore, ICAM-1–
mediated interactions segregate IPS from GVHD injury.
MATERIALS AND METHODS
Mice
B10.BR (H2k), C57BL/6 (H2b), and ICAM-1–/– mice
(backcrossed for more than 10 generations to C57BL/6 mice)
were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice were housed in microisolator cages in the Speciﬁc
Pathogen–Free facility of the University of Minnesota and
cared for according to the Research Animal Resources guide-
lines of our institution. For BMT, donors were 8 to 12 weeks
of age and recipients were used at 8 to 10 weeks of age. Our
animal facility, during repeated extensive evaluations over the
study period, found Sentinel mice that were negative for
15 known murine viruses including those that can contribute
to pneumonitis (eg, cytomegalovirus, pneumonia virus of
mice, and K-virus). In addition, representative mice receiving
cytotoxic therapy in combination with immune suppression
(ie, Cy and total body irradiation [TBI]) were examined and
found to have no evidence of virus-induced pathology.
Pre-BMT Treatment and Conditioning
C57BL/6 or ICAM-1–/– mice received phosphate-
buffered saline (PBS) or Cy (Cytoxan; Bristol Myers Squibb,
Seattle, WA), 120 mg/kg per day intraperitoneally (IP) on
days –3 and –2 pre-BMT. All mice were lethally irradiated
on the day before BMT (7.5 Gy TBI) by x-ray at a dose rate
of 0.41 Gy/minute as described [33].
Bone Marrow Transplantation
Our BMT protocol has been described previously [34].
Brieﬂy, donor B10.BR BM was T-cell depleted (TCD) with
anti-Thy 1.2 monoclonal antibody (MoAb) (clone 30-H-12,
rat IgG2b, kindly provided by Dr. David Sachs, Charlestown,
MA) plus complement (Nieffenegger Co, Woodland, CA).
B6 or ICAM-1–/– recipient mice received transplants via cau-
dal vein of 20 × 106 (prior to depletion) TCD marrow cells
with or without 5 × 106 or 15 × 106 natural killer (NK)-
cell–depleted (PK136, anti-NK1.1 plus complement) spleen
cells (BMS) as a source of IPS- and GVHD-causing T cells.
Bronchoalveolar Lavage
Mice were euthanized with sodium pentobarbitol and
the thoracic cavity partially dissected. The trachea was can-
nulated with a 19-gauge needle and infused with 0.5 mL PBS
and withdrawn. This was repeated 2 more times and a total
of 1.5 mL BAL ﬂuid was collected per mouse. BAL ﬂuid was
centrifuged at 4°C for 10 minutes at 1000g to pellet the cells
and stored at –80°C. BAL ﬂuid total protein was determined
by the bicinchoninic acid (Sigma, St. Louis, MO) method
with bovine serum albumin as the standard. The level of
nitrite was determined by the Greiss method after conver-
sion of nitrate to nitrite using NADH-dependent nitrate
reductase (Calbiochem, La Jolla, CA).
Serum Collection
At the time of sacriﬁce, blood was collected by cardiac
puncture and placed immediately at 4°C; the serum was sep-
arated at 4°C and stored at –80°C.
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Chemokine/Cytokine Level Determination
Serum and BAL levels of macrophage inflammatory
protein (MIP)-1α, MIP-1β, MIP-2, monocyte chemotactic
protein (MCP)-1, KC, IFN-γ, and TNF-α were determined
by sandwich enzyme-linked immunoassay (ELISA) (sensitiv-
ity, 1.5 to 3 pg/mL) using murine-speciﬁc commercial kits
(R&D Systems, Minneapolis, MN). Levels of lymphotactin,
6CKINE (Exodus-2) and IP-10 (CRG-2) were determined
by sandwich ELISA (sensitivity, 1 pg/mL) empirically devel-
oped using specific MoAbs and recombinant murine pro-
teins (R&D Systems).
Frozen Tissue Preparation
Following euthanasia on day 3 post-BMT, the thoracic
cavity was partially dissected and a mixture of 0.5 mL Opti-
mal Cutting Temperature compound (OCT; Miles Inc,
Elkhart, IN) and PBS (3:1 ratio, respectively) was infused
via the trachea into lungs. Lung, colon, and liver tissues
were arranged in aluminum foil cups with OCT, snap-
frozen in liquid nitrogen, and stored at –80°C.
Histologic Assessment
Cryosections (6 µm) were acetone-fixed (5 minutes at
room temperature), stained by hematoxylin and eosin, and
tissues were assessed for GVHD on a 0-to-4 scale by a scor-
ing system previously described [35].
Immunohistochemistry
Following ﬁxation in acetone, cryosections (6µm) were
immunoperoxidase-stained using biotinylated MoAbs essen-
tially as described [17] using avidin-biotin blocking reagents,
avidin-biotin complex–peroxidase conjugate and diamino-
benzidine chromogenic substrate, purchased from Vector
Laboratories (Burlingame, CA). The biotinylated MoAbs
used were as follows: anti-CD54 (clone 3E2), anti-CD4
(clone GK1.5), anti-CD8 (clone 2.43), anti-Mac-1 (clone
M1/70) and anti-Gr-1 (clone RB6-8C5), all purchased from
Pharmingen (San Diego, CA). The number of positive cells
in the lung was quantitated as the percentage of nucleated
cells observed under 200× magnification (20× objective
lens). Four ﬁelds per lung were evaluated.
Lung Weights
Mice were euthanized with sodium pentobarbitol and the
thoracic cavity partially dissected. Lungs were exsanguinated
by perfusion with 1.0 mL saline via the right ventricle of the
heart. To maximize use of mice, the right lung (bilobed) was
used for weight determinations and the left lobe was
processed for tissue staining. For each mouse, the wet weight
was taken immediately after right lung removal from the tho-
rax. Lungs were dried overnight to a constant weight at 80°C
followed by determination of dry weights, and the wet/dry
weight ratio was calculated [36]. No correction for extravas-
cular blood content was used in the calculations.
Pressure-Volume Curves
Following full heart-lung excision, the lungs were sus-
pended via the trachea and kept moist with saline. Pressure-
volume (P-V) curves of air- and liquid-filled lungs were
determined as previously described [37,38]. Air was delivered
into the lungs via a tracheal cannula in 0.05-mL increments
with a syringe while measuring intratracheal pressure with a
transducer until 30 cm of H2O pressure was reached (total
lung capacity). Air was then withdrawn in 0.05-mL incre-
ments until pressure was atmospheric. This was repeated
3 times and data procured from the third series. Speciﬁc lung
compliance was calculated from the slope of the third deﬂa-
tion P-V curve from points ﬂanking 5 cm of H2O pressure
(which is considered normal breathing range) as follows:
∆ Volume/∆ Pressure
Av volume
where Volume is in mL, Pressure is in cm of H2O and Av vol-
ume = average volume over the pressure range used to gener-
ate the slope of the P-V curve (ie, ∆ Volume/∆ Pressure).
Statistical Analysis
Survival data were analyzed by lifetable methods using
the Mantel-Peto-Cox summary of chi-square. Other data
were analyzed by Analysis of Variance (ANOVA) or Student
t test. Probability (P) values less than or equal to.05 were
considered statistically signiﬁcant.
RESULTS
Increased ICAM-1 Expression in the Lungs of
AlloBMT Mice
We have previously shown that ICAM-1 is upregulated
in GVHD target organs (spleen, liver, colon) early following
alloBMT [17]. We first investigated whether ICAM-1
expression was upregulated in the lungs of alloBMT mice
with IPS. On day 7 post-BMT, ICAM-1 was shown to be
highly expressed in the lungs of allogeneic recipients of BM
and 15 × 106 spleen cells (Figure 1B) but not in syngeneic
recipients (Figure 1A). ICAM-1 staining was seen to localize
to cells composing the inﬂammatory inﬁltrate, parenchymal
epithelial cells and endothelium, consistent with known
expression of ICAM-1 following either irradiation or stimu-
lation by inflammatory mediators such as TNF-α. These
data indicate that ICAM-1 could be a suitable target for
investigation into the pathophysiology of IPS.
ICAM-1–/– Recipients Exhibit Accelerated 
GVHD-Induced Lethality Following AlloBMT
To induce GVHD that is associated with IPS in a fully
allogeneic setting, lethally irradiated ICAM-1+/+ or ICAM-1–/–
recipient mice received transplants of T-cell–depleted
B10.BR BM with or without 5 × 106 or 15 × 106 splenocytes.
Mice were segregated into those receiving Cy in addition to
TBI as part of a more intense conditioning regimen that
accelerates mortality and potentiates IPS. Because ICAM-1
is involved in many inﬂammatory reactions, we anticipated
that its deﬁciency may delay or dampen GVHD. However,
as is seen in Figure 2, lethally irradiated ICAM-1–/– recipi-
ents of allogeneic BM with a low dose of splenocytes (5 × 106)
exhibited an accelerated lethality compared with ICAM-1+/+
recipients (P < .004). This accelerated lethality was also seen
in similarly conditioned mice receiving 15 × 106 spleen cells,
(P = .01, not shown). Figure 2 also shows that more intense
Cy/TBI conditioning accelerated the mortality of both
ICAM-1+/+ and ICAM-1–/– mice so that both groups died at
the same rate. Total body weights paralleled the survival data
IPS and GVHD in ICAM-1–Deficient Mice
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(not shown). Therefore, ICAM-1–/– mice exhibit an increased
susceptibility to GVHD-mediated mortality.
IPS Manifestations Are Attenuated in ICAM-1–/–
Recipients Post–AlloBMT
Because ICAM-1–/– mice exhibited accelerated GVHD-
mediated mortality, and IPS is associated with GVHD, we
examined the lung to determine whether IPS also was
affected by the absence of host ICAM-1. Histologic exami-
nation and scoring of GVHD target organs revealed that
GVHD-induced lesions in the colon and liver were of
equivalent severity in both ICAM-1+/+ and ICAM-1–/– recipi-
ents but lung pathology was less severe in ICAM-1–/– mice
(Figure 3). As is seen in Figure 1C, there is no discernable
expression of ICAM-1 by recipient epithelium or endothe-
lium and only minimal ICAM-1 expression localized to a
few inﬁltrating donor cells. Next, we sought to determine
whether the pulmonary physiological changes we previously
described in murine IPS were affected. Figure 4 shows that
wet and dry lung weights increased by day 10 post-BMT in
ICAM-1+/+ recipients of allogeneic BMS versus ICAM-1+/+
mice receiving BM only (consistent with results of the
reverse strain combination [3]). Because both wet and dry
weights increased, the wet/dry weight ratio did not change
appreciably [3]. However, ICAM-1–/– recipient mice did not
exhibit this increase in lung weights. Furthermore, as shown
in the Table, total lung capacity and specific compliance
were not significantly affected in ICAM-1–/– recipients of
allogeneic BMS; these parameters were adversely affected in
ICAM-1+/+ mice. These data indicate that, although
GVHD-induced gut mucosal and liver lesions and mortality
were equal to ICAM-1+/+ mice with the BMT conditions
used, deﬁciency of ICAM-1 in the recipient lung resulted in
decreased manifestations of lung injury that otherwise lead
to barrier disruption and edema post-alloBMT.
Figure 1. Increased expression of intercellular adhesion molecule-1
(ICAM-1) in the lungs of ICAM-1+/+ allogeneic bone marrow trans-
plantation (alloBMT) recipients on day 7 posttransplantation. BMT
was performed as described in Materials and Methods on recipients
conditioned by cyclophosphamide and total body irradiation and given
T-cell–depleted bone marrow and 15 × 106 spleen cells. Lungs from
syngeneic recipients (A), ICAM-1+/+ alloBMT recipients (B), and
ICAM-1–/– alloBMT recipients (C) were harvested on day 7 after BMT
and cryosections were stained for ICAM-1 by immunohistochemistry
(magniﬁcation ×200). Representative photographs of 1 of 8 mice per
group examined (from 2 experiments) are shown.
Figure 2. Intercellular adhesion molecule-1 (ICAM-1)–/– recipients
exhibit accelerated mortality following allogeneic bone marrow transplan-
tation (alloBMT). Lethally irradiated (circles) or cyclophosphamide and
total body irradiation (Cy/TBI)-conditioned (squares) C57BL/6 ICAM-
1+/+ (open symbols) or ICAM-1–/– mice (closed symbols) were given
C57BL/6 T-cell–depleted (TCD) BM with 5 × 106 spleen cells. ICAM-
1–/– TBI-conditioned mice (closed circles) had a signiﬁcantly accelerated
mortality rate (P < .0004) compared with ICAM-1+/+ recipients (open cir-
cles), whereas the mortality rate was not different among Cy/TBI-condi-
tioned recipients. All recipients (ICAM-1+/+ or ICAM-1–/– conditioned by
TBI or Cy/TBI) given allogeneic BM alone exhibited 100% survival dur-
ing the time period studied (triangle). Data reﬂect 8 mice per group, rep-
resentative of 2 experiments. * indicates ICAM-1–/– and ICAM-1+/+ recipi-
ents given BM alone and exhibiting the same proportion survival; BMS,
TCD BM cells with natural killer cell–depleted spleen cells.
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Host ICAM-1 Expression Is Necessary for
Augmenting the Inflammatory Cell Influx Into the
Lung Post-AlloBMT
In our characterization of murine IPS, we described the
phenotype of the inflammatory cell influx that comprised
host monocytes/macrophages, donor CD4 and CD8 T cells
and neutrophils. Because IPS manisfestations were amelio-
rated in ICAM-1–/– recipients, we wanted to determine
whether the inflammatory cell influx had been affected by
the absence of host ICAM-1. Figure 5 shows that the fre-
quency of CD4 T cells, CD8 T, cells and neutrophils were
signiﬁcantly lower in ICAM-1–/– recipients than in ICAM-1+/+
recipients as assessed by immunohistochemical staining of
lung cryosections. The frequencies of macrophages (that
were of host origin as determined by MHC class II expres-
sion) were also decreased in the ICAM-1–/– recipients but to
a lesser degree. Concurrently, the frequency of lymphocytes
in the BAL was significantly decreased in ICAM-1–/–
(ICAM-1+/+ versus ICAM-1–/–, 42.1% ± 10.5% versus 25.3% ±
4.3%, respectively, P = .0005,) and the total cellularity of the
BAL was 3.4 fold lower in ICAM-1–/– recipient mice (P =
.002). The frequencies of cells expressing the phenotypes
examined did not differ between ICAM-1+/+ or ICAM-1–/–
mice either before conditioning or on the day of transplanta-
tion indicating that the differences in frequencies after BMT
were not due to discrepancies present prior to transplanta-
tion (not shown). These data indicate that expression of
ICAM-1 in the recipient lung plays an important role in the
inﬂammatory process post-BMT.
Decreased Chemokine Production in the Lungs of
ICAM-1–/– Mice Post-AlloBMT
We have documented that inﬂammatory cytokines and
chemokines that attract monocytes, lymphocytes, and neu-
trophils are upregulated in the lung beginning as early as
day 3 post-BMT [6]. Because leukocyte recruitment post-
BMT was affected by the absence of ICAM-1 in the lung,
we examined the effect on the cytokine and chemokine pro-
ﬁles in the BAL ﬂuid and serum in these recipients. Figure 6
shows that the BAL fluid levels of the inflammatory
cytokines IFN-γ and TNF-α are significantly lower in
ICAM-1–/– mice on day 7 post-BMT. Furthermore, the lev-
els of the T-cell chemokines lymphotactin, MIP-1α, and
MIP-1β are signiﬁcantly decreased in ICAM-1–/– compared
with ICAM-1+/+ recipients in which the production of these
chemokines is T-cell dependent. The monocyte chemoat-
tractant MCP-1 was also decreased in ICAM-1–/– recipient
BAL ﬂuid but to a lesser extent and did not reach statistical
signiﬁcance. These ﬁndings in cytokine and chemokine lev-
els are consistent with the decrease in inﬁltrating T cells and,
to a lesser extent, macrophages in the lungs of ICAM-1–/–
recipients post-BMT. In contrast, the circulating levels of
these mediators in the sera of the same mice did not differ
between ICAM-1+/+ and knockout recipients and were ele-
vated to the same degree (data not shown).
Figure 3. Intercellular adhesion molecule-1 (ICAM-1)–/– recipients
exhibited decreased lung pathology but equivalent graft-versus-host
disease (GVHD)-induced lesions in the colon and liver post–allogeneic
bone marrow transplantation (post-alloBMT). ICAM-1–/– or ICAM-1+/+
C57BL/6 mice were conditioned by cyclophosphamide and total body
irradiation and given B10.BR T-cell–depleted (TCD) BM and 15 × 106
spleen cells. GVHD was scored according to our previously docu-
mented scoring system by microscopic analysis of hematoxylin and
eosin–stained cryosections of tissues taken on day 7 post-alloBMT [29].
Data are presented as mean score ± SD of 6 mice per group. *P < .05
(ICAM-1–/– versus ICAM-1+/+). BMS indicates TCD BM cells with nat-
ural killer cell–depleted spleen cells.
Figure 4. Intercellular adhesion molecule-1 (ICAM-1)–/– recipients did
not have increased lung weights post–allogeneic bone marrow trans-
plantation (post-alloBMT). ICAM-1–/– or ICAM-1+/+ C57BL/6 mice
were conditioned by cyclophosphamide and total body irradiation and
given B10.BR T-cell–depleted BM alone or with 15 × 106 spleen cells.
Wet and dry lung weights were determined on day 10 post-alloBMT
and the percentage increase in weight over the BM control for that
recipient group (that did not differ from nonmanipulated controls) is
shown. Data shown are mean percentage increase for 6 mice per group.
*P < .05 indicates a signiﬁcant increase in weight. BMS indicates TCD
BM cells with natural killer cell–depleted spleen cells.
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Another chemokine known to be a potent attractant for
T cells is 6CKINE, also called Exodus-2, produced by
endothelium, dendritic cells and T cells [39]. Exodus-2 was
found to be elevated in the BAL fluid, beginning at the
time of transplantation through day 7, to the same extent
with similar kinetics in both groups of recipients (day 7,
BMS ICAM-1–/– versus BMS ICAM-1+/+, 2334 ± 756 versus
3047 ± 1116 [P = .3], respectively, representing a 25-30 fold
increase over normal BAL fluid). This indicates that the
lungs of ICAM-1–/– mice are not completely deficient in
T-cell–attracting chemokine production post-BMT. At the
time of transplantation, the T-cell attractant IP-10 (pro-
duced by many cell types including endothelium, ﬁbroblasts,
and monocytes) was elevated approximately 4-fold above
normal levels to the same degree in both groups (ICAM-1+/+
versus ICAM-1–/–, 91.5 ± 39.9 versus 80.5 ± 25.3, respec-
tively, P = .6). Furthermore, the production of the neu-
trophil attractants KC and MIP-2 (sources of which could
be endothelium, fibroblasts, alveolar macrophages, and
bronchial epithelium) were also found to not differ between
the 2 groups of recipients (data not shown). These data indi-
cate that the production of the chemokines MIP-1α, MIP-1β,
and lymphotactin may not only be T-cell dependent but
may be donor T-cell derived in this IPS model, whereas the
production of other chemokines, such as IP-10, Exodus-2,
KC, and MIP-2, begins following pre-BMT conditioning
and is predominantly host-derived.
DISCUSSION
We have shown, through the use of ICAM-1–/– recipient
mice, that ICAM-1 plays a major role in the recruitment of
inflammatory cells into the lung during the generation of
IPS post-alloBMT. ICAM-1–/– recipients did not exhibit the
manifestations of severe IPS normally seen in our murine
model. Specifically, they did not have an increase in wet-
and dry-lung weights nor did they have significantly
decreased lung compliance or total lung capacity. Further-
more, the influx of inflammatory cells was dramatically
dampened as was the production of many inflammatory
mediators and chemokines that are normally upregulated in
the lung during IPS. Not all chemokines were reduced; the
T-cell attractants Exodus-2 and IP-10 were found in similar
amounts in the BAL fluids of ICAM-1+/+ and ICAM-1–/–
recipients, emphasizing either the critical role of ICAM-1
in T-cell recruitment and/or the lesser role of these chemo-
kines in IPS. The BAL levels of chemokines KC and MIP-2,
known to attract neutrophils, were not affected, indicating
that ICAM-1 is critical to the recruitment of neutrophils
into the lung or that KC and MIP-2 are not responsible for
neutrophil recruitment. In contrast, systemic levels of all of
the above mediators examined were unaffected, GVHD-
induced lesions in the liver and colon did not differ in sever-
ity regardless of ICAM-1 expression, and GVHD-mediated
mortality was not abrogated but, in fact, was accelerated.
These data implicate ICAM-1 as a discerning element segre-
gating IPS from GVHD.
We demonstrate increased expression of ICAM-1 in the
lungs of allogeneic-BMT recipients with IPS injury as we
had previously shown for the liver, spleen and colon during
GVHD [17]. It has been demonstrated that ICAM-1 pro-
duction is induced in pulmonary microvascular endothelium
following thoracic irradiation, and the lack of increased
expression in syngeneic recipients at day 7 post-BMT is
consistent with the kinetics of transient increase and return
to baseline by this timepoint [25,40].
ICAM-1–/– allo-BMT recipients had significantly
reduced infiltration of T cells, neutrophils, and, to a lesser
extent, monocytes. Although IPS is T-cell dependent,
many factors probably contribute to lung injury in our
murine IPS model and the reduction in lung injury in the
ICAM-1–/– mice is most likely a combined result of the
decrease in different effector mechanisms. First, the
decrease in CD8+ T cells could translate into a decrease in
the number of cytolytic effectors; it has been shown in
other studies that ICAM-1 is critical to the recruitment of
effector CD8+ T cells to sites of viral infection [41]. In our
study, concomitant with the decrease in CD8+-cell fre-
quency, we also observed a decrease in the frequency of cells
expressing mRNA for granzymes, using in situ hybridiza-
tion (data not shown).
Second, it is known that crosslinking of ICAM-1 signals
the oxidative burst in neutrophils [42] and that ICAM-1:
Mac-1 (CD11b)-dependent adhesion augments reactive
oxygen release by neutrophils [43]. In another model of lung
injury following hepatic ischemia/reperfusion, ICAM-1 was
shown to mediate neutrophil inﬂux into the lung with ensu-
ing pulmonary injury [44]. The abrogation in neutrophil
inﬂux and decrease in macrophage migration into the lung,
in the current study, has important implications for the
production of reactive oxygen species by these cells that,
when combined with nitric oxide (NO), form peroxynitrite,
a highly toxic molecule that is produced in the lungs of
Cy/TBI-conditioned mice following alloBMT [5]. In sup-
port of this interpretation, we found that the lungs of
ICAM-1–/– mice had decreased capacity for NO produc-
tion as shown by determination of the levels of nitrite in
the BAL fluid on day 7 post-alloBMT (ICAM-1+/+ versus
ICAM-1–/–, 7.20 ± 1.77 µM versus 5.05 ± 0.92 µM, respec-
tively) concomitant with decreased levels of total protein,
another index of lung injury (0.42 ± 0.27 mg/mL versus
0.15 ± 0.03 mg/mL, ICAM-1+/+ versus ICAM-1–/–).
Speciﬁc Lung Compliance and Total Lung Capacity Is Not 
Signiﬁcantly Compromised in ICAM-1–Deﬁcient Recipients Following 
Allogeneic BMT*
Specific Compliance, Total Lung
Inoculum Recipient 1/cm H2O Pressure Capacity (mL)
BM ICAM-1+/+ 0.135 ± 0.017 (9) 0.59 ± 0.18 (9)
BMS ICAM-1+/+ 0.100 ± 0.030 (6)† 0.38 ± 0.14 (6)†
BM ICAM-1–/– 0.121 ± 0.015 (9) 0.59 ± 0.15 (9)
BMS ICAM-1–/– 0.114 ± 0.022 (5) 0.46 ± 0.11 (5)
*Lungs were excised en bloc with the heart from mice on day 7
post-BMT and pressure-volume loops performed as described. Mean
values ± standard deviation are shown. Numbers in brackets indicate
number of mice in group. BMT indicates bone marrow transplantation;
ICAM-1, intercellular adhesion molecule-1; BMS, T-cell–depleted BM
cells with natural killer cell–depleted spleen cells.
†P < .03 compared to BM control mice.
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The infiltration of macrophages/antigen-presenting
cells into the lungs of ICAM-1–/– recipients was decreased to
a lesser extent compared with that of the other cell types,
consistent with reports of lack of impairment of antigen-
presenting–cell emigration into ICAM-1-deficient lungs
probably because these cells also use vascular cell adhesion
molecule-1 (VCAM-1) to adhere to endothelium [45] in
addition to using other pathways [46]. Blocking of ICAM-1
has been shown not to inhibit monocyte migration across
nonstimulated alveolar epithelial cells, but it can inhibit
migration across TNF-α–stimulated epithelium and migra-
tion of monocytes in the presence of MCP-1 [47]. These
effects are consistent with our ﬁndings in this study in which
we found a decrease in macrophage accumulation despite
the presence of increased BAL levels of MCP-1 that we
have previously shown to be produced by pulmonary cells
prior to monocyte inﬂux [6].
The decreased number of inﬁltrating T cells was accom-
panied by significantly reduced BAL levels of IFN-γ and
chemokines associated with T-cell migration such as lympho-
tactin, MIP-1α, and MIP-1β. ICAM-1 binds to LFA-1 on
lymphocytes, and crosslinking of LFA-1 by ICAM-1 induces
the secretion of IFN-γ [48] that is produced by Th1 cells.
The localization of alloreactive Th1 cells in the lung is medi-
ated by ICAM-1 [32]. Crosslinking of LFA-1 by ICAM-1 also
induces production MIP-1α and MIP-1β by T cells [49].
This effect of crosslinking implies that, in our IPS model, the
donor T cells may be the source of these mediators whose
production serves to further enhance the migration of more
cells to the inﬂamed lung as has been shown for MIP-1α [50].
Although monocytes and macrophages can produce MIP-1α
upon binding to ICAM-1 [51,52], the source for these
chemokines is most likely T cells because other monocyte-
associated mediators such as MCP-1 and TNF-α were not
reduced as dramatically in the BAL ﬂuid, and the increase in
MIP-1α accompanies the inﬂux of T cells [6].
Although ICAM-1 deﬁciency in the recipient mice may
alter the kinetics of the inﬂammatory response in the lung
with a delay in IPS development, this effect on IPS develop-
ment was not possible to evaluate in this model because of
Figure 5. Decreased percentage of inﬂammatory cell inﬁltrates in the lungs of intercellular adhesion molecule-1 (ICAM-1)–/– mice post–allogeneic
bone marrow transplantation (post-alloBMT). ICAM-1–/– or ICAM-1+/+ C57BL/6 mice were conditioned by cyclophosphamide and total body irra-
diation and given B10.BR T-cell–depleted (TCD) BM alone or with 15 × 106 spleen cells. Immunohistochemistry with the indicated antibody speci-
ﬁcities was done on cryosections of lungs taken on day 7 post-alloBMT. Data shown are the mean number of positive cells in the lungs, quantitated
as the percentage of nucleated cells (magniﬁcation ×200), of 6 mice per group. Error bars represent 1 SD. *ICAM-1–/– versus ICAM-1+/+ recipients
(comparing BMS [TCD BM cells with natural killer cell–depleted spleen cells] groups), P < .05.
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the accelerated GVHD-mediated mortality exhibited by
these mice. At the cell doses used (15 × 106 splenocytes, that
normally induce IPS) only rarely did ICAM-1–/– mice live
10 days post-BMT regardless of what conditioning regimen
was used. The paradox of a decrease in lung injury in the
absence of ICAM-1 in the face of severe GVHD-induced
liver and mucosal lesions and accelerated mortality was not
entirely unexpected. It has been shown that antibodies to
ICAM-1 can attenuate lung injury caused by diet-induced
pancreatitis although pancreatic injury is unaffected [53].
Furthermore, in a baboon model of acute sepsis-induced
lung injury, anti-CD54 antibody–treated animals exhibited
increased mortality and liver injury, whereas pulmonary
injury parameters were unaffected [54]. However, these
authors did report a decrease in alveolar macrophage inﬂux
in the lungs of anti-CD54–treated septic animals. This is
consistent with ICAM-1 playing a role in the dissociation of
systemic injury from lung injury. The reason for the
increased mortality remains unclear. Anti-CD54 has been
shown to increase inflammatory cytokines such as IL-1β,
Figure 6. Intercellular adhesion molecule-1 (ICAM-1)–/– recipients had decreased levels of inﬂammatory cytokines and chemokines in their bron-
choalveolar lavage (BAL) ﬂuid on day 7 post-alloBMT. ICAM-1–/– or ICAM-1+/+ C57BL/6 mice were conditioned by cyclophosphamide and total
body irradiation and given B10.BR T-cell–depleted BM alone or with 15 × 106 spleen cells. Lungs were lavaged on day 7 post-alloBMT and the
BAL ﬂuid analyzed by enzyme-linked immunosorbent assay. Data shown are mean levels ± SD for 6 mice per group. *ICAM-1–/– versus ICAM-1+/+
recipients (comparing BMS [TCD BM cells with natural killer cell–depleted spleen cells] groups), P < .05.
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IL-6, IL-8, and TNFRI in sepsis [55]. However, we did not
see any differences in circulating serum concentrations of a
large panel of inflammatory cytokines and chemokines
including IFN-γ, TNF-α, IL-6, MCP-1, MIP-2, MIP-1α,
and MIP-1β (data not shown) consistent with the study of
others showing that ICAM-1–/– mice are not impaired in
inﬂammatory cytokine production [56]. Alternatively, accel-
erated mortality could be due to impaired responses to
normally non-lethal pathogens especially in an immuno-
compromised host. However, there is no correlation between
bacterial clearance and survival in ICAM-1–/– mice [57].
In summary, these studies demonstrate that host
ICAM-1 expression plays a critical role in the generation of
IPS post-alloBMT and may be a suitable target for thera-
peutic intervention in patients at high risk for IPS injury.
However, the accelerated GVHD observed in ICAM-1–/–
recipients is a cause for caution in implementing such
approaches in clinical trials.
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